Sage Financial Statements From 2010 to 2024

SAGE Stock  USD 5.47  0.08  1.44%   
Sage Therapeutic financial statements provide useful quarterly and yearly information to potential Sage Therapeutic investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Sage Therapeutic financial statements helps investors assess Sage Therapeutic's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Sage Therapeutic's valuation are summarized below:
Gross Profit
-319.3 M
Market Capitalization
339.5 M
Enterprise Value Revenue
2.0962
Revenue
106.4 M
Earnings Share
(5.57)
There are over one hundred nineteen available fundamental trend indicators for Sage Therapeutic, which can be analyzed over time and compared to other ratios. Investors should ensure to double-check all of Sage Therapeutic's current performance against the performance from 2010 to 2024 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2 B. The current year's Enterprise Value is expected to grow to about 1.8 B

Sage Therapeutic Total Revenue

144.3 Million

Check Sage Therapeutic financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sage Therapeutic's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.3 M, Interest Expense of 17.1 M or Selling General Administrative of 144.2 M, as well as many indicators such as Price To Sales Ratio of 14.25, Dividend Yield of 0.0 or PTB Ratio of 1.7. Sage financial statements analysis is a perfect complement when working with Sage Therapeutic Valuation or Volatility modules.
  
Check out the analysis of Sage Therapeutic Correlation against competitors.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.

Sage Therapeutic Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets873.1 M882.3 M693.6 M
Slightly volatile
Other Current Liabilities41.5 M62.1 M33 M
Slightly volatile
Total Current Liabilities59.3 M82.7 M47.2 M
Slightly volatile
Property Plant And Equipment Net11.8 M6.4 M9.4 M
Slightly volatile
Accounts Payable11.5 M10.3 M9.3 M
Slightly volatile
Cash67.4 M71 M225.3 M
Pretty Stable
Non Current Assets Total20.5 M12.9 M16.3 M
Slightly volatile
Non Currrent Assets Other8.4 M6.5 M6.7 M
Slightly volatile
Other Assets7.3 M6.9 M2.8 M
Slightly volatile
Cash And Short Term Investments829.1 M753.2 M658.6 M
Slightly volatile
Common Stock Shares Outstanding45.7 M59.8 M39.6 M
Slightly volatile
Liabilities And Stockholders Equity873.1 M882.3 M693.6 M
Slightly volatile
Other Current Assets21.1 M30.3 M16.7 M
Slightly volatile
Total Liabilities70.5 M82.7 M58.2 M
Slightly volatile
Property Plant And Equipment Gross13.2 M13.9 M10.5 M
Slightly volatile
Total Current Assets852.6 M869.4 M677.3 M
Slightly volatile
Property Plant EquipmentM3.3 M3.9 M
Slightly volatile
Other Liabilities109.2 K115 K565.8 K
Very volatile
Net Tangible Assets977.9 M1.4 B727.1 M
Slightly volatile
Common Stock Total Equity5.3 K6.9 K4.5 K
Slightly volatile
Capital SurpluseB3.8 B1.5 B
Slightly volatile
Non Current Liabilities Other8.5 M5.3 M5.6 M
Slightly volatile
Deferred Long Term Asset Charges512.8 K576.9 K628.2 K
Slightly volatile
Common Stock5.4 K6.9 K4.5 K
Slightly volatile
Net Invested Capital1.3 B799.5 M849.6 M
Slightly volatile
Net Working Capital1.3 B786.6 M841.8 M
Slightly volatile
Capital Stock6.2 K6.9 K5.4 K
Slightly volatile
Short and Long Term Debt Total4.9 M5.2 M29.3 M
Slightly volatile
Capital Lease Obligations4.9 M5.2 M29.3 M
Slightly volatile
Short Term Debt10.9 M10.3 M11.4 M
Slightly volatile
Net Receivables42.7 M84.4 M24.2 M
Slightly volatile

Sage Therapeutic Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.3 M1.4 MM
Slightly volatile
Selling General Administrative144.2 M274.5 M114.8 M
Slightly volatile
Other Operating Expenses363.6 M666.3 M290 M
Slightly volatile
Research Development215.9 M356.2 M172.4 M
Slightly volatile
Total Operating Expenses363.2 M664.1 M289.6 M
Slightly volatile
Preferred Stock And Other Adjustments1.8 M2.1 M2.2 M
Slightly volatile
Selling And Marketing Expenses53.9 M51.3 M24.2 M
Slightly volatile
Net Interest Income37.9 M36.1 M10.7 M
Slightly volatile
Interest Income37.9 M36.1 M10.7 M
Slightly volatile
Reconciled Depreciation2.1 M1.3 M1.3 M
Slightly volatile
Non Recurring22.2 M25 M27.2 M
Slightly volatile

Sage Therapeutic Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow297.8 M164 M236.8 M
Slightly volatile
Other Cashflows From Financing Activities5.7 MM15.6 M
Very volatile
Depreciation1.3 M1.4 MM
Slightly volatile
Capital Expenditures525.4 K553 K985.8 K
Pretty Stable
Total Cash From Financing Activities5.7 MM181.4 M
Pretty Stable
End Period Cash Flow68.7 M72.3 M226.1 M
Pretty Stable
Stock Based Compensation66.7 M73.4 M48.9 M
Slightly volatile
Change To Netincome70.3 M69.1 M48.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.2514.998113
Slightly volatile
Days Sales Outstanding339356946
Slightly volatile
Stock Based Compensation To Revenue0.810.84863.9215
Slightly volatile
Capex To Depreciation0.380.3971.7557
Slightly volatile
EV To Sales13.5214.2366107
Slightly volatile
Payables Turnover0.220.20920.0631
Slightly volatile
Sales General And Administrative To Revenue3.023.17539.0342
Slightly volatile
Research And Ddevelopement To Revenue3.914.120511.8297
Slightly volatile
Capex To Revenue0.00610.00640.0877
Pretty Stable
Cash Per Share12.1812.587413.0183
Slightly volatile
Days Payables Outstanding1.7 K1.7 K11.2 K
Slightly volatile
Income Quality0.680.99830.8523
Pretty Stable
Current Ratio10.1610.506111.0998
Slightly volatile
Receivables Turnover1.081.02420.4505
Slightly volatile
Graham Number36.3852.1639.233
Slightly volatile
Debt To Equity0.00610.00650.0293
Slightly volatile
Capex Per Share0.00880.00920.0222
Pretty Stable
Revenue Per Share1.371.44492.8158
Very volatile
Interest Debt Per Share0.0820.08630.3411
Slightly volatile
Debt To Assets0.00560.00590.0257
Slightly volatile
Days Of Payables Outstanding1.7 K1.7 K11.2 K
Slightly volatile
Ebt Per Ebit1.080.93380.9925
Very volatile
Long Term Debt To Capitalization0.00390.00410.0202
Slightly volatile
Total Debt To Capitalization0.00610.00640.0283
Slightly volatile
Debt Equity Ratio0.00610.00650.0293
Slightly volatile
Quick Ratio10.2210.48811.1604
Slightly volatile
Net Income Per E B T1.061.090.9748
Slightly volatile
Cash Ratio0.820.85795.5736
Very volatile
Days Of Sales Outstanding339356946
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.0011.0132
Slightly volatile
Fixed Asset Turnover11.1713.553110.8155
Very volatile
Debt Ratio0.00560.00590.0257
Slightly volatile
Price Sales Ratio14.2514.998113
Slightly volatile
Asset Turnover0.130.0980.1075
Very volatile
Gross Profit Margin1.050.9750.9775
Pretty Stable

Sage Therapeutic Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market CapB1.3 B2.2 B
Slightly volatile
Enterprise Value1.8 B1.2 BB
Slightly volatile

Sage Fundamental Market Drivers

Cash And Short Term Investments753.2 M

Sage Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Sage Therapeutic Financial Statements

Sage Therapeutic stakeholders use historical fundamental indicators, such as Sage Therapeutic's revenue or net income, to determine how well the company is positioned to perform in the future. Although Sage Therapeutic investors may analyze each financial statement separately, they are all interrelated. For example, changes in Sage Therapeutic's assets and liabilities are reflected in the revenues and expenses on Sage Therapeutic's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Sage Therapeutic. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue86.5 M144.3 M
Cost Of Revenue2.2 M2.1 M
Stock Based Compensation To Revenue 0.85  0.81 
Sales General And Administrative To Revenue 3.18  3.02 
Research And Ddevelopement To Revenue 4.12  3.91 
Capex To Revenue 0.01  0.01 
Revenue Per Share 1.44  1.37 
Ebit Per Revenue(6.71)(7.04)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:
Check out the analysis of Sage Therapeutic Correlation against competitors.
For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.57)
Revenue Per Share
1.76
Quarterly Revenue Growth
3.371
Return On Assets
(0.30)
Return On Equity
(0.49)
The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.